|Bid||27.11 x 1000|
|Ask||0.00 x 0|
|Day's Range||29.14 - 29.31|
|52 Week Range||23.99 - 29.47|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.75%|
Seth Klarman's Baupost Group appears to be digging into beaten up health-care stocks. In a 13-F filing submitted to the Securities & Exchange Commission on Monday, the Boston-based asset management firm reported that it took a new position in pharmaceutical distribution company McKesson (MCK) and added to its stakes in Allergan (AGN) and Cardinal Health (CAH). Meanwhile, Baupost sold out of its position in Qualcomm (QCOM), nearly halved its stake in Dell Technologies (DVMT), and cut its shares in Avis Budget Group (CAR) by 74%.
The Zacks Analyst Blog Highlights: Global X Guru Index ETF, AlphaClone Alternative Alpha ETF, Goldman Sachs Hedge Industry VIP ETF and Direxion iBillionaire Index ETF
These funds replicate the investing styles and predictions of market gurus, providing a solid and well-diversified portfolio, which seeks to outperform the broader market.
Among the certainties on Wall Street are the following: Hedge funds usually carry high fees while exchange-traded funds usually carry low fees. Some ETFs grant investors exposure to hedge fund strategies ...
Sales force development In 1Q17, Valeant Pharmaceuticals (VRX) had 40% more sales personnel to promote its gastrointestinal franchise than it did in 1Q16. This was a result of the company’s…
Dermatology pricing trends Valeant Pharmaceuticals’ (VRX) dermatology business witnessed intense pricing pressure in 2016, due to a change in the company’s distribution model in 4Q15. While Valeant previously ...
Gastrointestinal business In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) franchise saw its revenue fall due to the loss of patent protection for drugs Zegerid and Glumetza in the US…
Net profit margins Valeant Pharmaceuticals (VRX) has projected its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) to fall $3.6 billion–$3.7 billion. Besides lower revenue, ...
In the first nine months of 2016, the Bausch + Lomb/International segment reported revenues of ~$3.4 billion, which equals year-over-year (or YoY) growth of ~0.4%.
With the Express Scripts agreement, Horizon Pharma’s net sales in 2017 are expected to rise. The probability of a top-line expansion has boosted investor sentiment.